PriceTargets.com logo

Atlas Arteria - MAQAF Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $6.54
  • Forecasted Upside: 17.85 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$5.55 As of 08/17/2022 01:00 AM ET
▼ -0.06 (-1.07%)

This chart shows the closing price for MAQAF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Atlas Arteria Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MAQAF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MAQAF

Analyst Price Target is $6.54
▲ +17.85% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Atlas Arteria in the last 3 months. The average price target is $6.54, with a high forecast of $6.66 and a low forecast of $6.41. The average price target represents a 17.85% upside from the last price of $5.55.

This chart shows the closing price for MAQAF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 2 investment analysts is to hold stock in Atlas Arteria. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/25/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
8/23/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/19/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
5/20/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
7/19/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
8/18/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/25/2022ABN AmroDowngradeHold$6.41
3/25/2022MacquarieDowngradeHold$6.66
6/1/2021Jefferies Financial GroupInitiated CoverageHold
10/29/2020The Goldman Sachs GroupDowngradeBuy ➝ Neutral
4/28/2020The Goldman Sachs GroupUpgradeNeutral ➝ Buy
1/7/2019The Goldman Sachs GroupUpgradeSell ➝ Neutral
(Data available from 8/18/2017 forward)

News Sentiment Rating

-0.14 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/20/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/19/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/21/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/20/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/20/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/19/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/19/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/18/2022

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
Atlas Arteria logo
Atlas Arteria Limited owns, develops, and operates toll roads. It holds a 13.4% interest in 22-kilometer toll road investors partnership II (TRIP II), the concessionaire for Dulles Greenway toll road located in Virginia, the United States. The company was formerly known as Macquarie Atlas Roads Limited and changed its name to Atlas Arteria Limited in May 2018. Atlas Arteria Limited was incorporated in 2009 and is based in Melbourne, Australia.
Read More

Today's Range

Now: $5.55
Low: $5.55
High: $5.55

50 Day Range

MA: $5.57
Low: $5.29
High: $5.82

52 Week Range

Now: $5.55
Low: $4.54
High: $5.82

Volume

108 shs

Average Volume

4,369 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Atlas Arteria?

The following Wall Street analysts have issued stock ratings on Atlas Arteria in the last twelve months: ABN Amro, and Macquarie.
View the latest analyst ratings for MAQAF.

What is the current price target for Atlas Arteria?

2 Wall Street analysts have set twelve-month price targets for Atlas Arteria in the last year. Their average twelve-month price target is $6.54, suggesting a possible upside of 17.9%. Macquarie has the highest price target set, predicting MAQAF will reach $6.66 in the next twelve months. ABN Amro has the lowest price target set, forecasting a price of $6.41 for Atlas Arteria in the next year.
View the latest price targets for MAQAF.

What is the current consensus analyst rating for Atlas Arteria?

Atlas Arteria currently has 2 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in MAQAF, but not buy more shares or sell existing shares.
View the latest ratings for MAQAF.

What other companies compete with Atlas Arteria?

Other companies that are similar to Atlas Arteria include Aena S.M.E., CK Infrastructure, Transurban Group, 3 Sixty Risk Solutions and 8i Enterprises Acquisition. Learn More about companies similar to Atlas Arteria.

How do I contact Atlas Arteria's investor relations team?

Atlas Arteria's physical mailing address is 50 Martin Place, Sydney, New South. The company's listed phone number is 61 4 3849 3692. The official website for Atlas Arteria is www.atlasarteria.com. Learn More about contacing Atlas Arteria investor relations.